Normalized creatinine-to-cystatin C ratio

Biomarker

1 paper1 finding

Humans1

Associations

Cardiometabolic multimorbidity

downin humans1OR 0.72

1 study

Normalized creatinine-to-cystatin C ratio lowers the risk of cardiometabolic multimorbidity in humans (OR 0.72, 95% CI 0.62 to 0.85).
“The risk of CMM was significantly decreased with per standard deviation increase of NCCR (odds ratio, 0.72; 95% confidence interval, 0.62 to 0.85) after adjustment for confounders (P<0.001).”
Humansmedian 4-year follow-upn = 5,849
Normalized Creatinine-to-Cystatin C Ratio and Risk of Cardiometabolic Multimorbidity in Middle-Aged and Older Adults: Insights from the China Health and Retirement Longitudinal Study
Diabetes & metabolism journalJan 20, 2025

Latest

1 in 12 months

Cardiovascular DiabetologyOct 10

Combined blood marker linked to cardiovascular disease risk

An observational study followed 5,474 Chinese participants from 2011 to 2020 and linked higher marker values to progression to clinical cardiovascular disease.An observational study followed 5,474 Chinese participants from 2011 to 2020 and linked higher marker values to progression to clinical cardiovascular disease.

Cohort study of 5,474 peopleCardiovascular disease

Paper

Diabetes & Metabolism JournalJan 20

Normalized Creatinine-to-Cystatin C Ratio and Risk of Cardiometabolic Multimorbidity in Middle-Aged and Older Adults: Insights from the China Health and Retirement Longitudinal Study

Cohort study of 5,849 peopleCystatin C